Quilizumab is an Afucosylated Humanized Anti-M1 Prime Therapeutic Antibody

ISSN: 2212-7046 (Online)
ISSN: 2212-7038 (Print)


Volume 1, 2 Issues, 2014






Clinical Anti-Inflammatory & Anti-Allergy Drugs

Aims & ScopeAbstracted/Indexed in


Submit Abstracts Online Submit Manuscripts Online

Editor-in-Chief:
Giovanni Passalacqua
Allergy & Respiratory Diseases
Department of Internal Medicine
University of Genova
Genova
Italy


View Full Editorial Board

Subscribe Purchase Articles Order Reprints


Quilizumab is an Afucosylated Humanized Anti-M1 Prime Therapeutic Antibody

Author(s): Hans D. Brightbill, Yuwen L. Lin, Zhonghua Lin, Martha Tan, Y. Gloria Meng, Mercedesz Balazs, Shan Chung and Lawren C. Wu

Affiliation: Department of Immunology, Genentech Inc., 1 DNA Way, MS 34, South San Francisco, CA 94080, USA.

Abstract

Depletion of IgE-switched B cells may be an efficacious therapy for the treatment of allergic asthma. A humanized monoclonal IgG1 antibody against the M1 prime segment of human membrane IgE on IgE-switched B cells can reduce serum IgE by depleting IgE-producing cells. Here we report that removal of the core fucose in the Fc glycan of this anti-M1 prime antibody increases its binding affinity for human FcγRIII receptors compared to the wildtype antibody. The enhancement in binding to FcγRIII results in increased antibody potency for the in vitro depletion of IgE-positive cells in antibody-dependent cell-mediated cytotoxicity assays and for the in vivo reduction of serum IgE in mice reconstituted with human immune cells. This afucosylated anti-M1 prime antibody is known as quilizumab and is in clinical development for the treatment of allergic asthma.

Keywords: ADCC, afucosylation, asthma, IgE, quilizumab.

Download Free Rights and Permissions

Article Details

Volume: 1
Issue Number: 1
First Page: 24
Last Page: 31
Page Count: 8
DOI: 10.2174/22127038114019990003
Advertisement

Related Journals




Webmaster Contact: urooj@benthamscience.org Copyright © 2014 Bentham Science